Trial Profile
Nivolumab With Standard of Care Chemotherapy for the First Line Treatment of Peripheral T Cell Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Etoposide (Primary) ; Nivolumab (Primary) ; Prednisone (Primary) ; Vincristine (Primary)
- Indications Anaplastic large cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 06 Jan 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 06 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition